BioLizard
ActiveSummary
BioLizard has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.67M and a net result of €324k. Equity is growing by ~31.4% per year across the filed fiscal years. Its solvency ranks better than 65% of 191 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability53▼-22
Solvency95▲+1
Growth78=
Track record100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €260k at 30 days acceptable
Liquidity ample (current ratio 3.67 against 3.78 in 2024; short-term debt: 21.4% and cash: 15.7% of total assets), and 30.1% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
69.9%
Return on assets
6.2%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
28 d early
2024
29 d early
2023
9 d early
2022
27 d early
2021
34 d early
2020
8 d early
2019
23 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€324k▲ 42.8%
2024 · €227k
2019: €-242klowest in 7 years
2020: €58k▲ +124% vs 2019
2021: €429k▲ +644% vs 2020
2022: €597k▲ +39.1% vs 2021highest in 7 years
2023: €481k▼ -19.4% vs 2022
2024: €227k▼ -52.8% vs 2023
2025: €324k▲ +42.8% vs 2024
2019 → 2025
Working capital
€3.00M▲ 12.1%
2024 · €2.67M
2019: €104klowest in 7 years
2020: €493k▲ +374% vs 2019
2021: €844k▲ +71.2% vs 2020
2022: €2.18M▲ +159% vs 2021
2023: €2.24M▲ +2.4% vs 2022
2024: €2.67M▲ +19.6% vs 2023
2025: €3.00M▲ +12.1% vs 2024highest in 7 years
2019 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€908k-€2.02M▲ 123%€2.49M▲ 23.4%€2.98M▲ 19.6%€3.67M▲ 23.1%
2021: €908klowest in 5 years
2022: €2.02M▲ +123% vs 2021
2023: €2.49M▲ +23.4% vs 2022
2024: €2.98M▲ +19.6% vs 2023
2025: €3.67M▲ +23.1% vs 2024highest in 5 years
Operating result€369k-€657k▲ 77.9%€611k▼ 6.9%€240k▼ 60.7%€129k▼ 46.3%
2021: €369k
2022: €657k▲ +77.9% vs 2021highest in 5 years
2023: €611k▼ -6.9% vs 2022
2024: €240k▼ -60.7% vs 2023
2025: €129k▼ -46.3% vs 2024lowest in 5 years
Net result€429k-€597k▲ 39.1%€481k▼ 19.4%€227k▼ 52.8%€324k▲ 42.8%
2021: €429k
2022: €597k▲ +39.1% vs 2021highest in 5 years
2023: €481k▼ -19.4% vs 2022
2024: €227k▼ -52.8% vs 2023lowest in 5 years
2025: €324k▲ +42.8% vs 2024
Result per fiscal year
Operating resultNet result
The operating result has fallen three years in a row; 2025 is 46% below 2024 and is the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €5.26M
Fixed assets
€1.13M ▲ 72.6%
Current assets
€4.12M ▲ 13.3%
Equity and liabilities €5.26M
Equity
€3.67M ▲ 23.1%
Provisions
€104k ▼ 21.4%
Debt
€1.48M ▲ 25.6%
Debt's share of the balance-sheet total rises from 27.4% to 28.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€376k▼
2024 · €418k
Cash flow
€571k▲
2024 · €405k
Current ratio
3.67▼
2024 · 3.78
Debt to equity
0.40▲
2024 · 0.39
ROE
8.8%▲
2024 · 7.6%
ROA
6.2%▲
2024 · 5.3%
Interest coverage
3.20▼
2024 · 12.43
Debt ≤ 1 year
€1.12M▲
2024 · €963k
Income taxes
€-73k▼
2024 · €72k
Staff costs
€3.53M▲
2024 · €3.34M
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 58 lines
Balance sheet
Code20242025
Assets
Total assets20/58€4.29M€5.26M▲
Fixed assets21/28€657k€1.13M▲
Intangible fixed assets21€487k€656k▲
Tangible fixed assets22/27€150k€136k▼
Plant, machinery and equipment23€659€334▼
Furniture and vehicles24€58k€48k▼
Other tangible fixed assets26€91k€87k▼
Financial fixed assets28€20k€342k▲
Current assets29/58€3.64M€4.12M▲
Amounts receivable after more than one year29€1.27M€1.14M▼
Other amounts receivable291€1.27M€1.14M▼
Amounts receivable within one year40/41€1.61M€2.04M▲
Trade receivables40€1.57M€1.47M▼
Other amounts receivable41€41k€574k▲
Cash at bank and in hand54/58€682k€827k▲
Deferred charges and accrued income490/1€75k€119k▲
Equity and liabilities
Total equity and liabilities10/49€4.29M€5.26M▲
Equity10/15€2.98M€3.67M▲
Contributions10/11€467k€467k=
Capital10€467k€467k=
Issued capital100€467k€467k=
Reserves13€443k€358k▼
Non-distributable reserves130/1€47k€47k=
Legal reserve130€47k€47k=
Tax-exempt reserves132€397k€312k▼
Profit (loss) carried forward14€1.73M€2.14M▲
Investment grants15€348k€713k▲
Provisions and deferred taxes16€132k€104k▼
Deferred taxes168€132k€104k▼
Amounts payable17/49€1.18M€1.48M▲
Amounts payable within one year42/48€963k€1.12M▲
Current portion of amounts payable after more than one year42-€186k
Trade debts44€528k€500k▼
Suppliers440/4€528k€500k▼
Taxes, remuneration and social security45€436k€438k▲
Taxes450/3€63k€44k▼
Remuneration and social security454/9€373k€394k▲
Accrued charges and deferred income492/3€215k€355k▲
Income statement
Code20242025
Non-recurring operating income76A€11k€167▼
Remuneration, social security and pensions62€3.34M€3.53M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€178k€247k▲
Other operating charges640/8€9k€2k▼
Non-recurring operating charges66A-€2k
Gross operating margin9900€3.77M€3.91M▲
Operating profit (loss)9901€240k€129k▼
Financial income75/76B€64k€212k▲
Recurring financial income75€64k€212k▲
Financial charges65/66B€34k€117k▲
Recurring financial charges65€34k€117k▲
Profit (loss) for the period before taxes9903€271k€223k▼
Transfer from deferred taxes780€28k€28k=
Income taxes67/77€72k€-73k▼
Profit (loss) for the period9904€227k€324k▲
Transfer from tax-exempt reserves789€85k€85k=
Profit (loss) for the period to be appropriated9905€312k€409k▲
Appropriation of the result
Profit (loss) to be appropriated9906€1.73M€2.14M▲
Profit (loss) brought forward from the previous period14P€1.41M€1.73M▲
Social balance
Average headcount (FTE)908733.134.2▲
The notes to these accounts (14 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Accounts by statement
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €11k | €167 | ▼ 98.5% |
| Remuneration, social security and pensions62 | €747k | €1.89M | €2.89M | €3.34M | €3.53M | ▲ 5.7% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €110k | €171k | €125k | €178k | €247k | ▲ 38.9% |
| Other operating charges640/8 | €1k | €1k | €2k | €9k | €2k | ▼ 77.4% |
| Non-recurring operating charges66A | - | - | €149k | - | €2k | - |
| Gross operating margin9900 | €1.23M | €2.72M | €3.78M | €3.77M | €3.91M | ▲ 3.8% |
| Operating profit (loss)9901 | €369k | €657k | €611k | €240k | €129k | ▼ 46.3% |
| Financial income75/76B | €95k | €131k | €133k | €64k | €212k | ▲ 228% |
| Recurring financial income75 | €95k | €131k | €133k | €64k | €212k | ▲ 228% |
| Financial charges65/66B | €5k | €29k | €123k | €34k | €117k | ▲ 249% |
| Recurring financial charges65 | €5k | €29k | €123k | €34k | €117k | ▲ 249% |
| Profit (loss) for the period before taxes9903 | €460k | €759k | €622k | €271k | €223k | ▼ 17.7% |
| Transfer from deferred taxes780 | - | €9k | €28k | €28k | €28k | = |
| Income taxes67/77 | €30k | €171k | €169k | €72k | €-73k | ▼ 200% |
| Profit (loss) for the period9904 | €429k | €597k | €481k | €227k | €324k | ▲ 42.8% |
| Transfer from tax-exempt reserves789 | - | - | €85k | €85k | €85k | = |
| Profit (loss) for the period to be appropriated9905 | €429k | €597k | €566k | €312k | €409k | ▲ 31.1% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €1.52M | €3.13M | €3.42M | €4.29M | €5.26M | ▲ 22.4% |
| Fixed assets21/28 | €314k | €397k | €467k | €657k | €1.13M | ▲ 72.6% |
| Intangible fixed assets21 | €291k | €224k | €262k | €487k | €656k | ▲ 34.8% |
| Tangible fixed assets22/27 | €24k | €154k | €185k | €150k | €136k | ▼ 9.5% |
| Plant, machinery and equipment23 | - | €800 | €1k | €659 | €334 | ▼ 49.4% |
| Furniture and vehicles24 | €24k | €60k | €80k | €58k | €48k | ▼ 17.2% |
| Other tangible fixed assets26 | - | €93k | €104k | €91k | €87k | ▼ 4.2% |
| Financial fixed assets28 | - | €19k | €20k | €20k | €342k | ▲ 1,588% |
| Current assets29/58 | €1.21M | €2.73M | €2.95M | €3.64M | €4.12M | ▲ 13.3% |
| Amounts receivable after more than one year29 | - | €657k | €902k | €1.27M | €1.14M | ▼ 10.5% |
| Other amounts receivable291 | - | €657k | €902k | €1.27M | €1.14M | ▼ 10.5% |
| Amounts receivable within one year40/41 | €703k | €1.06M | €1.25M | €1.61M | €2.04M | ▲ 26.7% |
| Trade receivables40 | €602k | €1.06M | €1.24M | €1.57M | €1.47M | ▼ 6.6% |
| Other amounts receivable41 | €101k | - | €12k | €41k | €574k | ▲ 1,299% |
| Cash at bank and in hand54/58 | €444k | €948k | €712k | €682k | €827k | ▲ 21.3% |
| Deferred charges and accrued income490/1 | €60k | €68k | €86k | €75k | €119k | ▲ 59.6% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €1.52M | €3.13M | €3.42M | €4.29M | €5.26M | ▲ 22.4% |
| Equity10/15 | €908k | €2.02M | €2.49M | €2.98M | €3.67M | ▲ 23.1% |
| Contributions10/11 | €467k | €467k | €467k | €467k | €467k | = |
| Capital10 | €467k | €467k | €467k | €467k | €467k | = |
| Issued capital100 | €467k | €467k | €467k | €467k | €467k | = |
| Reserves13 | €47k | €47k | €528k | €443k | €358k | ▼ 19.2% |
| Non-distributable reserves130/1 | €47k | €47k | €47k | €47k | €47k | = |
| Legal reserve130 | €47k | €47k | €47k | €47k | €47k | = |
| Tax-exempt reserves132 | - | - | €482k | €397k | €312k | ▼ 21.4% |
| Profit (loss) carried forward14 | €251k | €849k | €1.41M | €1.73M | €2.14M | ▲ 23.7% |
| Investment grants15 | €144k | €660k | €85k | €348k | €713k | ▲ 105% |
| Provisions and deferred taxes16 | - | €189k | €161k | €132k | €104k | ▼ 21.4% |
| Deferred taxes168 | - | €189k | €161k | €132k | €104k | ▼ 21.4% |
| Amounts payable17/49 | €613k | €915k | €764k | €1.18M | €1.48M | ▲ 25.6% |
| Amounts payable after more than one year17 | €250k | €250k | - | - | - | - |
| Financial debts170/4 | €250k | €250k | - | - | - | - |
| Amounts payable within one year42/48 | €363k | €544k | €715k | €963k | €1.12M | ▲ 16.7% |
| Current portion of amounts payable after more than one year42 | - | - | - | - | €186k | - |
| Trade debts44 | €138k | €267k | €246k | €528k | €500k | ▼ 5.2% |
| Suppliers440/4 | €138k | €267k | €246k | €528k | €500k | ▼ 5.2% |
| Taxes, remuneration and social security45 | €226k | €276k | €467k | €436k | €438k | ▲ 0.6% |
| Taxes450/3 | €145k | €101k | €102k | €63k | €44k | ▼ 29.8% |
| Remuneration and social security454/9 | €81k | €176k | €365k | €373k | €394k | ▲ 5.8% |
| Other amounts payable47/48 | - | - | €2k | - | - | - |
| Accrued charges and deferred income492/3 | - | €122k | €49k | €215k | €355k | ▲ 65.2% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €429k | €597k | €481k | €227k | €324k | ▲ 42.8% |
| + Depreciation and write-downs630 | €110k | €171k | €125k | €178k | €247k | ▲ 38.9% |
| Operating cash flow (approximation) | €539k | €769k | €607k | €405k | €571k | ▲ 41.1% |
| Investment in fixed assets (approximation) | - | €-254k | €-196k | €-367k | €-723k | ▼ 97.0% |
| Change in cash | - | €504k | €-237k | €-30k | €145k | ▲ 587% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
03-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
02-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
22-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
04-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Highest result since 2019net €597k ▲39.1%
Operating result €657k, net result €597k, both a record.
31-12
Financial
Equity above €2MEq €2.02M ▲123%
3 profitable years in a row build equity to €2.02M.
27-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
31-12
Financial
Equity above €500kEq €908k ▲168%
2 profitable years in a row build equity to €908k.
23-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Back to profitnet €58k
Net result €58k after one loss-making year.
31-12
Financial
Equity above €200kEq €339k
Equity rises from €-42k to €339k.
08-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 8 acts read
About the unread acts
We know of 8 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
8 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Gent · 1 establishment unit since 2018
Ground area
7,465 m²
Building footprint
899 m²
Volume, LiDAR
3,475 m³
Parcel 44808H0746/00B000, Flanders · tallest building 8.2 m, ±2 floors. Linked by address, not a title deed.
17
companies at this address
See who is registered here
1 establishment unit
BioLizard
since 20182.285.071.263
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44808H0746/00B000 | Flanders | 7,465 m² | 1 · 899 m² | 8.2 m · 2 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 to 2025 · 15 entries · 910,161 EUR awarded · 451,023 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2025 | 6 | 809,404 EUR | 409,626 EUR |
| 2024 | 4 | 75,628 EUR | 19,148 EUR |
| 2023 | 3 | 12,319 EUR | 9,439 EUR |
| 2022 | 2 | 12,810 EUR | 12,810 EUR |
Schemes
Ontwikkelingsproject
Baekeland-mandaat
Kmo-groeisubsidie: steun voor groeitrajecten bij kmo's (stopgezet)
Subsidies voor internationaal ondernemen
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Show 1 more
Vlaams opleidingsverlof (VOV)
European Union, budget
2022 · 3 entries · 792,923 EUR in total| Year | Entries | awarded |
|---|---|---|
| 2022 | 3 | 792,923 EUR |
Projects
REPO4EU - PRECISION DRUG REPURPOSING FOR EUROPE AND THE WORLD
European research
2 projects · 792,927 EUR EU contributionProgrammes
Horizon Europe
Projects
Precision drug REPurpOsing For EUrope and the world
SPAtial single-CEll omics research training for MELanoma precision medicine
Similar companies · same sector, comparable size
The Conference Board, Inc.
BE 0417.517.890
New-York · Eq €3,633,571
Santero Therapeutics
BE 0765.790.155
Charleroi · Eq €3,631,776
Indigo Diabetes
BE 0666.442.557
Gent · Eq €3,618,622
CANCER STATE THERAPEUTICS
BE 0793.113.273
Charleroi · Eq €3,738,662
Obulytix
BE 0803.351.624
Gent · Eq €3,820,634
Of 1,177 companies in sector 72109 we hold annual accounts for 716. 335 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded26-11-2018
Fiscal year end31-12
Activities, NACEBEL 2025
72109Other research and development on natural sciences
78200Temporary employment agencies and other provision of personnel
74999Other professional, scientific and technical activities
77400Rental and leasing activities
Contact
E-mail
gerben.menschaert@gmail.comGent
Scores and ratios are computed by Checked and are not a credit decision.